Quick Answer
Tvardi Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $20.73 million for the year ending 2025.
- Tvardi Therapeutics, Inc. showed a decrease of -34.4% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Tvardi Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2013: $690.0 thousand | Q2 2013: $21.18 million | Q3 2013: $17.73 million | Q1 2014: $67.04 million | Q2 2014: $62.81 million | Q3 2014: $58.39 million | Q1 2015: $47.42 million | Q2 2015: $43.19 million | Q3 2015: $111.12 million | Q1 2016: $7.92 million | Q2 2016: $3.55 million | Q3 2016: $5.43 million | Q1 2017: $5.31 million | Q2 2017: $9.42 million | Q3 2017: $11.79 million | Q1 2018: $11.88 million | Q2 2018: $17.80 million | Q3 2018: $96.73 million | Q1 2019: $14.19 million | Q2 2019: $18.49 million | Q3 2019: $34.71 million | Q1 2020: $17.04 million | Q2 2020: $56.97 million | Q3 2020: $75.28 million | Q1 2021: $22.52 million | Q2 2021: $22.34 million | Q3 2021: $22.99 million | Q1 2022: $21.36 million | Q2 2022: $46.72 million | Q3 2022: $42.81 million | Q1 2023: $47.39 million | Q2 2023: $58.25 million | Q3 2023: $62.88 million | Q1 2024: $47.00 million | Q2 2024: $49.24 million | Q3 2024: $37.06 million | Q1 2025: $34.22 million | Q2 2025: $20.65 million | Q3 2025: $21.42 million.
- Over the full 15 years of available data (2011 to 2025), Tvardi Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 406.1%.
- Historical annual values: Fiscal year 2025: $20.73 million | Fiscal year 2024: $31.61 million | Fiscal year 2023: $51.78 million | Fiscal year 2022: $63.74 million | Fiscal year 2021: $13.45 million | Fiscal year 2020: $31.68 million | Fiscal year 2019: $18.31 million | Fiscal year 2018: $15.08 million | Fiscal year 2017: $9.39 million | Fiscal year 2016: $12.09 million | Fiscal year 2015: $15.10 million | Fiscal year 2014: $52.66 million | Fiscal year 2013: $12.36 million | Fiscal year 2012: $1.12 million | Fiscal year 2011: $4.10 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: